Autopsy report · NCT03212807

Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL

Cause of deathRegulatory or ethics Automatic label, confidence 0.9, unverified. How labels are made.

“FDA Hold for Combination Studies using Imids and PD1/PDL1 Compounds”

The sponsor’s own words in the registry.

Life of this trial

Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status: Withdrawn
Phase: Phase 2
Sponsor: Singapore General Hospital
Sponsor type: University, hospital or other
Conditions: EBV Related Non-Hodgkin's Lymphoma; Primary CNS Lymphoma; Primary Testicular Lymphoma
Interventions: Durvalumab; Lenalidomide
Participants: 0
Sites: 4
Countries: Singapore

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.